J. Blagg

发表

Physiochemical drug properties associated with in vivo toxicological outcomes.

J. Hughes, Enoch S. Huang, David A. Price, 2008, Bioorganic & medicinal chemistry letters.

A selective chemical probe for exploring the role of CDK8 and CDK19 in human disease

Gary Box, Julian Blagg, Paul Workman, 2015, Nature chemical biology.

Structure–Activity Relationships for In vitro and In vivo Toxicity

Julian Blagg, J. Blagg, 2006 .

1-(2-Phenoxyphenyl)methanamines: SAR for dual serotonin/noradrenaline reuptake inhibition, metabolic stability and hERG affinity.

Julian Blagg, P. Fish, J. Blagg, 2008, Bioorganic & medicinal chemistry letters.

Scaffold Diversity in Medicinal Chemistry Space

Sarah R. Langdon, Julian Blagg, J. Blagg, 2013 .

Molecular profiling and combinatorial activity of CCT068127: a potent CDK2 and CDK9 inhibitor

Nathan Brown, Julian Blagg, Paul Workman, 2018, Molecular oncology.

Physicochemical drug properties associated with in vivo toxicological outcomes: a review

Nigel Greene, Julian Blagg, David A. Price, 2009, Expert opinion on drug metabolism & toxicology.

Analysis of water patterns in protein kinase binding sites

Caterina Barillari, Julian Blagg, Anna L. Duncan, 2011, Proteins.

Diverse Functionalization of Aurora-A Kinase at Specified Surface and Buried Sites by Native Chemical Modification

R. Bayliss, J. Blagg, Meirion Richards, 2014, PloS one.

Reduction of Neuropathic and Inflammatory Pain through Inhibition of the Tetrahydrobiopterin Pathway

K. Channon, Michio W. Painter, N. Ferreirós, 2015, Neuron.

Bornane sultam-directed asymmetric synthesis of crystalline, enantiomerically pure syn aldols

J. Blagg, W. Oppolzer, Inés Rodríguez, 1990 .

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

P. Workman, A. Faisal, M. Valenti, 2012, Leukemia.

Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy

A. Faisal, M. Valenti, A. K. de Haven Brandon, 2017, British Journal of Cancer.

Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.

R. V. van Montfort, A. Faisal, N. Cronin, 2016, Journal of medicinal chemistry.

Naturally Occurring Mutations in the MPS1 Gene Predispose Cells to Kinase Inhibitor Drug Resistance.

R. V. van Montfort, P. Workman, A. Faisal, 2015, Cancer research.

The Aurora Kinase Inhibitor CCT137690 Downregulates MYCN and Sensitizes MYCN-Amplified Neuroblastoma In Vivo

S. Robinson, P. Workman, A. Faisal, 2011, Molecular Cancer Therapeutics.

2,8-Disubstituted-1,6-Naphthyridines and 4,6-Disubstituted-Isoquinolines with Potent, Selective Affinity for CDK8/19

F. Rohdich, P. Workman, D. Musil, 2016, ACS medicinal chemistry letters.

Aurora kinase inhibitors: novel small molecules with promising activity in acute myeloid and Philadelphia-positive leukemias

J. Blagg, A. Moore, A. Pearson, 2010, Leukemia.

Ligand discrimination between active and inactive activation loop conformations of Aurora-A kinase is unmodified by phosphorylation† †Electronic supplementary information (ESI) available. See DOI: 10.1039/c8sc03669a

L. Ying, C. Dodson, J. Blagg, 2019, Chemical science.

Microfluidic Mobility Shift Assay for Real-Time Analysis of Peptide N-Palmitoylation

K. Boxall, J. Blagg, A. Magee, 2017, SLAS discovery : advancing life sciences R & D.

8-Substituted Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives As Potent, Cell Permeable, KDM4 (JMJD2) and KDM5 (JARID1) Histone Lysine Demethylase Inhibitors

G. F. Ruda, O. Fedorov, C. Bountra, 2016, Journal of medicinal chemistry.

Privileged Structures and Polypharmacology within and between Protein Families

R. V. van Montfort, P. Workman, Y. Le Bihan, 2018, ACS medicinal chemistry letters.

JARID2 is a direct target of the PAX3-FOXO1 fusion protein and inhibits myogenic differentiation of rhabdomyosarcoma cells

B. Al-Lazikani, M. Garrett, J. Shipley, 2013, Oncogene.

De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder

E. van Binsbergen, S. Twigg, A. Wilkie, 2019, American journal of human genetics.

The Deciphering Developmental Disorders Study (2019). De Novo Missense Substitutions in the Gene Encoding CDK8, a Regulator of the Mediator Complex, Cause a Syndromic Developmental Disorder. American Journal of Human Genetics 104 (4),

M. V. Dooren, S. Twigg, A. Wilkie, 2019 .

Epigenetics: Targeting leukemia on the DOT.

P. Workman, J. Blagg, J. Travers, 2011, Nature chemical biology.

Optimization of imidazo [4, 5-b] pyridine-based kinase inhibitors: identification of a dual FLT3/aur

Gary Box, Nathan Brown, Julian Blagg, 2012 .

Quizartinib-resistant FLT3-ITD acute myeloid leukemia cells are sensitive to the FLT3-Aurora kinase inhibitor CCT241736.

A. Faisal, M. Valenti, A. K. de Haven Brandon, 2020, Blood advances.

Regioselective C2-arylation of imidazo[4,5-b]pyridines.

J. Blagg, V. Bavetsias, J. Macdonald, 2013, Organic & biomolecular chemistry.

Imidazo[4,5-b]pyridine derivatives as inhibitors of Aurora kinases: lead optimization studies toward the identification of an orally bioavailable preclinical development candidate.

P. Workman, A. Faisal, R. Bayliss, 2010, Journal of medicinal chemistry.

Abstract B74: The dual FLT3-Aurora inhibitor CCT241736 overcomes resistance to selective FLT3 inhibition driven by FLT3 ligand and FLT3 point mutations in acute myeloid leukemia.

P. Workman, A. Faisal, M. Valenti, 2011 .

Molecular profiling and combinatorial activity of CCT068127

M. Noble, P. Workman, S. Whittaker, 2017 .

The development of non-steroidal dual inhibitors of both human 5α-reductase isozymes

P. Finn, J. Blagg, F. Macintyre, 1996 .

Microwave-assisted synthesis of 4-amino-3,5-dihalopyridines

J. Blagg, E. McDonald, M. Pichowicz, 2010 .

Design and synthesis of a functionally selective D3 agonist and its in vivo delivery via the intranasal route.

J. Blagg, A. Baxter, H. Verrier, 2007, Bioorganic & medicinal chemistry letters.

Design and synthesis of pyridazinone-based 5-HT(2C) agonists.

M. Andrews, K. Liu, G. McMurray, 2009, Bioorganic & medicinal chemistry letters.

From industry to academia

A. Hopkins, J. Blagg, 2008, Nature Reviews Drug Discovery.

Pyrimido[4,5-d]azepines as potent and selective 5-HT2C receptor agonists: design, synthesis, and evaluation of PF-3246799 as a treatment for urinary incontinence.

M. Andrews, A. Brown, P. Fish, 2011, Bioorganic & medicinal chemistry letters.

Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer

J. Welti, J. Blagg, J. D. de Bono, 2016, Clinical Cancer Research.

Assessing histone demethylase inhibitors in cells: lessons learned

G. F. Ruda, O. Fedorov, C. Bountra, 2017, Epigenetics & Chromatin.

Aurora Isoform Selectivity: Design and Synthesis of Imidazo[4,5-b]pyridine Derivatives as Highly Selective Inhibitors of Aurora-A Kinase in Cells

P. Workman, A. Faisal, K. Boxall, 2013, Journal of medicinal chemistry.

Discovery of Potent, Selective, and Orally Bioavailable Small-Molecule Modulators of the Mediator Complex-Associated Kinases CDK8 and CDK19

Julian Blagg, Paul Workman, Florence I. Raynaud, 2016, Journal of medicinal chemistry.

Small, non-peptide C5a receptor antagonists: part 2.

K. Beaumont, J. Blagg, Esther F. Schmid, 2008, Bioorganic & medicinal chemistry letters.

Chiral toluene-2,α-sultam auxiliaries: Asymmetric diels-alder reactions of N-enoyl derivatives

J. Blagg, W. Oppolzer, M. Wills, 1990 .

Stoichiometric organotransition metal complexes in organic synthesis

J. Blagg, 1995 .

Design and synthesis of piperazinylpyrimidinones as novel selective 5-HT(2C) agonists.

David W. Gordon, M. Andrews, A. Brown, 2009, Bioorganic & medicinal chemistry letters.

Chiral Toluene‐2,α‐sultam Auxiliaries: Asymmetric Alkylations, Acylations, and Aldolizations of N‐Acyl Derivatives.

J. Blagg, W. Oppolzer, M. Wills, 1992 .

Asymmetric Diels‐Alder reactions: X‐Ray crystal‐structure analysis of [N‐((E)‐But‐2‐enoyl)bornane‐10,2‐sultam]tetrachlorotitanium

G. Bernardinelli, J. Blagg, W. Oppolzer, 1989 .

Stoichiometric applications of organotransition metal complexes in organic synthesis

J. Blagg, 2010 .

Small, non-peptide C5a receptor antagonists: part 1.

K. Beaumont, J. Blagg, Esther F. Schmid, 2008, Bioorganic & medicinal chemistry letters.

Tetrahydroisoquinolines. Part 3. Stereoselective synthesis of cis- and trans-1,4-disubstituted N-methyl-1,2,3,4-tetrahydroisoquinolines as their tricarbonylchromium complexes

J. Blagg, S. Davies, S. J. Coote, 1987 .

Structure-Based Optimization of Potent, Selective, and Orally Bioavailable CDK8 Inhibitors Discovered by High-Throughput Screening.

Julian Blagg, Djordje Musil, Paul Czodrowski, 2016, Journal of medicinal chemistry.

a-Alkylation of a,a-Disubstituted Amines via ? 2 -Ketimine Complexes of Zirconocene

J. Blagg, R. Whitby, N. Coles, 1992 .

The highly stereoselective conversion of n,n-dimethylamphetamine into n-methylpseudoephedrine; A mimic of the enzyme mediated stereospecific benzylic h

J. Blagg, S. Davies, 1987 .

The diastereoselective functionalisation of arene tricarbonylchromium complexes containing a benzylic heteroatom substituent

C. Goodfellow, J. Blagg, S. Davies, 1987 .

The stereoselective synthesis of (–)-(8R)-methylcanadine via selective monocomplexation of canadine to chromium tricarbonyl

J. Blagg, S. Davies, 1986 .

Tetrahydroisoquinolines. Part 2. Synthesis of 4-substituted N-methyl-1,2,3,4-tetrahydroisoquinolines via regio- and stereo-selective elaboration of tricarbonyl(N-methyl-1,2,3,4-tetrahydroisoqumoline)chromium

J. Blagg, S. Davies, S. J. Coote, 1986 .

Elaboration of α-substituted benzyl alkyl ethers and sulphides by suppression of the Wittig and related rearrangements via complexation to tricarbonylchromium

C. Laughton, J. Blagg, S. Davies, 1986 .

Stereospecific conversion of N,N-dimethylamphetamine into N-methylpseudoephedrine

J. Blagg, S. Davies, 1985 .

4-Substituted N-methyl-1,2,3,4-tetrahydroisoquinolines: synthesis via stereoselective substitution of tricarbonyl(N-methyl-1,2,3,4-tetrahydroisoquinoline)chromium

J. Blagg, S. Davies, B. E. Mobbs, 1985 .

An improved procedure for N-formylation of secondary amines using chlorotrimethylsilane-imidazole-N,N-dimethylformamide

J. Blagg, M. Willis, D. Craig, 1992 .

Structure-reactivity correlations for the formation of zirconocene .eta.2-imine complexes from amines

M. C. Harris, J. Blagg, R. Whitby, 1994 .

Convergent synthesis of pyrrolidines, piperidines, perhydroazepines and tetrahydroisoquinolines via zirconocene η2-imine complexes

M. C. Harris, J. Blagg, R. Whitby, 1995 .

A practical procedure for the elaboration of amines via zirconocene η2-imine complexes

M. C. Harris, J. Blagg, R. Whitby, 1994 .

The promise and peril of chemical probes.

John P. Overington, Jian Jin, Matthieu Schapira, 2015, Nature chemical biology.

Erratum: The promise and peril of chemical probes (Nature Chemical Biology (2015) 11 (536-541))

John P. Overington, Jayme L. Dahlin, Christopher M. Austin, 2015 .

Orally bioavailable CDK9/2 inhibitor shows mechanism-based therapeutic potential in MYCN-driven neuroblastoma

Charles Y. Lin, J. Bradner, N. Gray, 2020, The Journal of clinical investigation.

Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans.

Steven W. Martin, A. Brown, D. Fradet, 2010, Journal of medicinal chemistry.

Development and evaluation of selective, reversible LSD1 inhibitors derived from fragments

Mark Cockerill, A. Mirza, J. Blagg, 2013 .

Double benzyne–furan cycloaddition and the assembly of 1,1′-binaphthyl and 1,1′-dinaphthyl ether systems

A. Barrett, J. Blagg, A. White, 2004 .

Structure-based design of imidazo[1,2-a]pyrazine derivatives as selective inhibitors of Aurora-A kinase in cells.

A. Faisal, R. Bayliss, Chongbo Sun, 2010, Bioorganic & medicinal chemistry letters.

Mechanism-Based Screen for G1/S Checkpoint Activators Identifies a Selective Activator of EIF2AK3/PERK Signalling

P. Workman, Stuart C. Wilson, G. Aherne, 2012, PloS one.

Small-molecule targeting of brachyury transcription factor addiction in chordoma

Christopher J. Ott, Ann E. Sizemore, Charles Y. Lin, 2019, Nature Medicine.

Donated chemical probes for open science

Anton Simeonov, Steve Hitchcock, Stefan Laufer, 2018, eLife.

Discovery of Potent, Orally Bioavailable, Small-Molecule Inhibitors of WNT Signaling from a Cell-Based Pathway Screen

F. Rohdich, T. Dale, P. Workman, 2015, Journal of medicinal chemistry.

Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy

J. Shipley, J. Blagg, S. Gatz, 2019, Pediatric blood & cancer.

Discovery of potent and selective CDK8 inhibitors from an HSP90 pharmacophore.

Julian Blagg, Djordje Musil, Paul Czodrowski, 2016, Bioorganic & medicinal chemistry letters.

Dynamic Equilibrium of the Aurora A Kinase Activation Loop Revealed by Single‐Molecule Spectroscopy

L. Ying, C. Dodson, J. Blagg, 2017, Angewandte Chemie.

A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.

T. Dale, P. Workman, K. Ewan, 2010, Cancer research.

Crystal structure of an Aurora-A mutant that mimics Aurora-B bound to MLN8054: insights into selectivity and drug design.

R. Bayliss, C. Dodson, J. Blagg, 2010, The Biochemical journal.

Chemical biology approaches to target validation in cancer.

Julian Blagg, Paul Workman, P. Workman, 2014, Current opinion in pharmacology.

The tetrahydrobiopterin pathway and pain.

A. Hopkins, J. Blagg, A. Naylor, 2010, Current opinion in investigational drugs.

Designing drugs for the treatment of female sexual dysfunction.

A. Brown, J. Blagg, D. Reynolds, 2007, Drug discovery today.

Structural Alerts for Toxicity

Julian Blagg, J. Blagg, 2010, Medicinal Chemistry for Practitioners.

Insights into Aurora-A Kinase Activation Using Unnatural Amino Acids Incorporated by Chemical Modification

R. Bayliss, J. Blagg, A. Thompson, 2013, ACS chemical biology.

The Metabolism and Toxicity of Furosemide in the Wistar Rat and CD-1 Mouse: a Chemical and Biochemical Definition of the Toxicophore

Julian Blagg, Iain Gardner, Dominic P. Williams, 2007, Journal of Pharmacology and Experimental Therapeutics.

Combining Mutational Signatures, Clonal Fitness, and Drug Affinity to Define Drug-Specific Resistance Mutations in Cancer

J. Blagg, T. Kaserer, 2018, Cell chemical biology.

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

Julian Blagg, Paul Workman, P. Workman, 2017, Cancer cell.

A public-private partnership to unlock the untargeted kinome.

Julian Blagg, Paul Workman, Bernhard Kuster, 2013, Nature chemical biology.

Choose and Use Your Chemical Probe Wisely to Explore Cancer Biology

P. Workman, J. Blagg, 2017, Cancer cell.

Design, Synthesis and Characterization of Covalent KDM5 Inhibitors

O. Fedorov, C. Bountra, A. Cribbs, 2018, Angewandte Chemie.

Scaffold Diversity of Exemplified Medicinal Chemistry Space

Sarah R. Langdon, Nathan Brown, Julian Blagg, 2011, J. Chem. Inf. Model..

Pyrido[3,4-d]pyrimidin-4(3H)-one metabolism mediated by aldehyde oxidase is blocked by C2-substitution

Y. Le Bihan, Alan T. Henley, F. Raynaud, 2016, Xenobiotica; the fate of foreign compounds in biological systems.

Evaluation of Germline BMP4 Mutation as a Cause of Colorectal Cancer

Nathan Brown, Julian Blagg, Richard S Houlston, 2011, Human mutation.

High Proliferation Rate and a Compromised Spindle Assembly Checkpoint Confers Sensitivity to the MPS1 Inhibitor BOS172722 in Triple-Negative Breast Cancers

R. V. van Montfort, A. Faisal, F. Raynaud, 2019, Molecular Cancer Therapeutics.

Fragment-Based Screening Maps Inhibitor Interactions in the ATP-Binding Site of Checkpoint Kinase 2

Ian Collins, Isaac M. Westwood, Nathan Brown, 2013, PloS one.

Introduction of a Methyl Group Curbs Metabolism of Pyrido[3,4-d]pyrimidine Monopolar Spindle 1 (MPS1) Inhibitors and Enables the Discovery of the Phase 1 Clinical Candidate N2-(2-Ethoxy-4-(4-methyl-4H-1,2,4-triazol-3-yl)phenyl)-6-methyl-N8-neopentylpyrido[3,4-d]pyrimidine-2,8-diamine (BOS172722)

R. V. van Montfort, A. Faisal, N. Cronin, 2018, Journal of medicinal chemistry.

Structure-Based Design of Orally Bioavailable 1H-Pyrrolo[3,2-c]pyridine Inhibitors of Mitotic Kinase Monopolar Spindle 1 (MPS1)

Isaac M. Westwood, Julian Blagg, Florence I. Raynaud, 2013, Journal of medicinal chemistry.

Structural Basis of Poly(ADP-ribose) Recognition by the Multizinc Binding Domain of Checkpoint with Forkhead-associated and RING Domains (CHFR)*

R. Bayliss, J. Blagg, Nathan Brown, 2010, The Journal of Biological Chemistry.

Assessing the mechanism and therapeutic potential of modulators of the human Mediator complex-associated protein kinases

S. Czasch, F. Rohdich, T. Dale, 2016, eLife.

C8-substituted pyrido[3,4-d]pyrimidin-4(3H)-ones: Studies towards the identification of potent, cell penetrant Jumonji C domain containing histone lysine demethylase 4 subfamily (KDM4) inhibitors, compound profiling in cell-based target engagement assays

G. F. Ruda, O. Fedorov, O. Rossanese, 2019, European journal of medicinal chemistry.

Characterization of Hedgehog Acyltransferase Inhibitors Identifies a Small Molecule Probe for Hedgehog Signaling by Cancer Cells

J. Blagg, A. Magee, E. Tate, 2016, ACS chemical biology.

Mapping the 3D structures of small molecule binding sites

Nathan Brown, Julian Blagg, Joshua Meyers, 2016, Journal of Cheminformatics.

Role for the Histone Demethylase KDM4B in Rhabdomyosarcoma via CDK6 and CCNA2: Compensation by KDM4A and Apoptotic Response of Targeting Both KDM4B and KDM4A

O. Rossanese, J. Shipley, J. Blagg, 2021, Cancers.

Discovery of potent & selective inhibitors of activated thrombin-activatable fibrinolysis inhibitor for the treatment of thrombosis.

M. Bunnage, K. Beaumont, J. Blagg, 2007, Journal of medicinal chemistry.

Scaffold-Focused Virtual Screening: Prospective Application to the Discovery of TTK Inhibitors

Sarah R. Langdon, Isaac M. Westwood, Rob L. M. van Montfort, 2013, J. Chem. Inf. Model..

Physicochemicaldrugproperties associatedwithin vivo toxicologicaloutcomes:areview

David A. Price, N. Greene, J. Blagg, 2009 .

Pharmacological options in the treatment of benign prostatic hyperplasia.

J. Blagg, B. Kenny, S. Ballard, 1997, Journal of medicinal chemistry.

Plane of Best Fit: A Novel Method to Characterize the Three-Dimensionality of Molecules

Nathan Brown, Julian Blagg, Nicholas C. Firth, 2012, J. Chem. Inf. Model..

Aurora kinase inhibition: a new light in the sky?

J. Blagg, S. Linardopoulos, 2015, Journal of medicinal chemistry.

Potent pyrimidinetrione-based inhibitors of MMP-13 with enhanced selectivity over MMP-14.

D. Danley, J. Pandit, E. Laird, 2005, Bioorganic & medicinal chemistry letters.

Characterisation of CCT271850, a selective, oral and potent MPS1 inhibitor, used to directly measure in vivo MPS1 inhibition vs therapeutic efficacy

A. Faisal, M. Valenti, A. K. de Haven Brandon, 2017, British Journal of Cancer.

MOARF, an Integrated Workflow for Multiobjective Optimization: Implementation, Synthesis, and Biological Evaluation

Nathan Brown, Julian Blagg, Nicholas C. Firth, 2015, J. Chem. Inf. Model..

Assessing histone demethylase inhibitors in cells: lessons learned

G. F. Ruda, O. Fedorov, C. Bountra, 2017, Epigenetics & Chromatin.

Potent and selective nonpeptidic inhibitors of procollagen C-proteinase.

Julian Blagg, P. Fish, R. Butt, 2007, Journal of medicinal chemistry.

Metabolism of the dual FLT-3/Aurora kinase inhibitor CCT241736 in preclinical and human in vitro models: Implication for the choice of toxicology species

A. Faisal, F. Raynaud, A. Hayes, 2019, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

Dual Inhibition of Aurora and FLT3 Kinases by CCT137690: A Novel Treatment Strategy Against FLT3-ITD Positive AML In Vitro and In Vivo

P. Workman, A. Faisal, M. Valenti, 2010 .

Resistance to Selective FLT3 Inhibitors, Driven by FLT3 Ligand and FLT3 Point Mutations, Can Be Overcome with the Dual FLT3-Aurora Kinase Inhibitor CCT241736,

P. Workman, A. Faisal, M. Valenti, 2011 .

Design and synthesis of pyridazinone-based 5-HT(2C) agonists.

M. Andrews, K. Liu, G. McMurray, 2009, Bioorganic & Medicinal Chemistry Letters.

Optimization of Imidazo[4,5-b]pyridine-Based Kinase Inhibitors: Identification of a Dual FLT3/Aurora Kinase Inhibitor as an Orally Bioavailable Preclinical Development Candidate for the Treatment of Acute Myeloid Leukemia

M. Valenti, A. K. de Haven Brandon, Alan T. Henley, 2012, Journal of Medicinal Chemistry.

A useful approach to identify novel small-molecule inhibitors of Wnt-dependent transcription.

T. Dale, P. Workman, K. Ewan, 2010, Cancer research.

Bioisosteres in De Novo Design

Julian Blagg, Nicholas C. Firth, Nathan J. Brown, 2013 .

Selective FLT3 inhibition of FLT3-ITD+ acute myeloid leukaemia resulting in secondary D835Y mutation: a model for emerging clinical resistance patterns

P. Workman, A. Faisal, M. Valenti, 2012, Leukemia.

Benzimidazole inhibitors of the protein kinase CHK2: Clarification of the binding mode by flexible side chain docking and protein–ligand crystallography

R. V. van Montfort, J. Blagg, I. Westwood, 2012, Bioorganic & medicinal chemistry.

The promise and peril of chemical probes (vol 11, pg 536, 2015)

John P. Overington, Jayme L. Dahlin, Christopher M. Austin, 2015 .

Characterization of Hedgehog Acyltransferase Inhibitors Identifies a Small Molecule Probe for Hedgehog Signaling by Cancer Cells

Edward W. Tate, J. Blagg, A. Magee, 2016, ACS chemical biology.

Catalytic inhibition of KDM1A in Ewing sarcoma is insufficient as a therapeutic strategy

J. Shipley, J. Blagg, S. Gatz, 2019, Pediatric blood & cancer.

Evaluation of APOBEC3B Recognition Motifs by NMR Reveals Preferred Substrates

M. Tortorici, R. V. van Montfort, A. Mirza, 2018, ACS chemical biology.

Discovery of a selective small-molecule melanocortin-4 receptor agonist with efficacy in a pilot study of sexual dysfunction in humans.

D. Fradet, M. Lansdell, D. Hepworth, 2010, Journal of medicinal chemistry.

Abstract 5450: Naturally occurring mutations in the MPS1 gene predispose cells to kinase inhibitor drug-resistance

P. Workman, A. Faisal, K. Boxall, 2015 .